Information Center: info@virotherapy.com

Information Center
info@virotherapy.com

Scientific Publications

View more Scientific Publications on PubMed

Oncolytic virotherapy: basic principles, recent advances and future directions

Oncolytic virus preclinical toxicology studies

Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir

4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period

Clinical landscape of oncolytic virus research in 2020

The Oncolytic Virus in Cancer Diagnosis and Treatment

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report

Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir.

Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient.

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®

Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are approved. The first, Rigvir, is an immunomodulator with anti-tumour effect

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery

Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro

Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report

Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports

Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumor in a retrospective study

Supplement Facts

Serving Size :

1 capsule

Servings Per Box:

1 capsule in moisture resistant sachet

Ingredients

Amount Per Capsule

% Daily Value

Whey protein isolate

190 mg

*

Traces of a genetically unmodified and non-pathogenic lyophilized ECHO-7 virus Rigvir

10 mg

+

Vitamin B2 (riboflavin)

5 mg

385%

* Daily Value for total fat, saturated fat, total carbohydrates, and sugars is <1% per serving.

† Daily Value not established.